Here we report the results of a phase IIa pilot study, performed in RA patients, who previously experienced a secondary failure of anti-TNF biologics

Here we report the results of a phase IIa pilot study, performed in RA patients, who previously experienced a secondary failure of anti-TNF biologics. 90 (n = 6), 180 (n = 12), or 360 g TNF-K (n = 12). The primary objective was to identify the best dose and schedule based on anti-TNF antibody titers. Clinical symptoms and safety were assessed during 12 months and solicited reactions for 7 days after each injection. == Results == The Zearalenone highest anti-TNF antibody response was detected in patients immunized with 360 g TNF-K and with 3 injections, although this difference was not significant with all other groups. Similar proportions of patients receiving TNF-K and placebo reported adverse events up to month 12. Serious adverse events were reported by 4 patients treated with TNF-K (13.3%) and 3 treated with Zearalenone placebo (30.0%), all unrelated to treatment. At month 12, DAS28-CRP, tender and swollen joint counts, and HAQ scores decreased significantly more in individuals who exhibited anti-TNF antibody response than in individuals who did not. == Conclusions == TNF-K restorative vaccination induced dose- and schedule-dependent anti-TNF antibodies in RA individuals and was well tolerated. Individuals who developed anti-TNF antibodies showed a pattern toward medical improvement. Even though most aggressive dose and routine, we.e. 360 mg dose administered 3 times, did show a strong pattern of higher antibody response, further studies are warranted to examine actually higher and more frequent doses in order to establish the best conditions for medical improvement. == Trial Sign up == ClinicalTrials.govNCT01040715 == Introduction == Rheumatoid arthritis (RA) is a chronic systemic immune mediated inflammatory disease that affects 0.5 to 1% of the population, resulting in major functional disability and improved mortality[1]. Hyperproduction of tumor necrosis element (TNF) produced by triggered monocytes and macrophages takes on a central part in RA, resulting in synovitis and articular matrix degradation[2]. The introduction of TNF focusing on drugs (anti-TNF) have changed dramatically the perspectives of Rabbit Polyclonal to BMP8B RA treatment over the last decade, with unprecedented results in terms of disease control and articular damage prevention[3]. Nevertheless, only 30 to 40% of anti-TNF treated individuals accomplished remission in controlled clinical tests[4], and even lower remission rates are explained in everyday practice[5]. An approximately related proportion reaches a functional status comparable to that of the general population[6]. Main or secondary restorative failures on anti-TNF medicines are frequent[7], and there is now evidence the induction of anti-drug antibodies could be a major factor to loss of response to this class of therapeutics, primarily with the use of anti-TNF monoclonal antibodies[8],[9]. These drawbacks of current anti-TNF treatments confirm that there is room for option ways to target this important proinflammatory cytokine. Among these, active immunization against TNF with TNF-Kinoid (TNF-K) is definitely a promising development[10],[11]. TNF-K consists of human being TNF (hTNF) coupled to a carrier protein, the keyhole limpet haemocyanin (KLH)[12]. This compound is able to break B cell tolerance to hTNF, therefore inducing the production of polyclonal, neutralizing anti-hTNF antibodies and circumventing the concern of anti-drug antibody induction[13]. The proof of concept of TNF-K applicability in RA was performed in hTNF transgenic mouse (TTg) model[14]. We shown the effectiveness of TNF-K in TTg, both on medical arthritis and histological joint swelling and damage[13],[15],[16]. The anti-TNF antibody response induced by TNF-K offers some characteristics that are fundamental for further developments: TNF-K does not sensitize T cells to native hTNF[13], the anti-hTNF antibody titers are produced as bell-shaped curve along time[15],[16], endogenous TNF does not boost the immune response[16]: only B cell tolerance toward TNF is definitely broken and only TNF-K could boost the immune response. Based on the proof of concept founded in experimental arthritis, TNF-K entered medical development. A Phase I medical trial, performed in Crohns disease individuals, showed it was well tolerated and immunogenic[17]. Here we statement the results of a phase IIa pilot study, performed in RA individuals, who previously experienced a secondary failure of anti-TNF biologics. We observed Zearalenone a production of anti-TNF antibodies and improvement of some medical parameters showing the relevance in humans of the anti-TNF restorative vaccination concept. == Methods == == Overall study design == This study was a phase II, randomized, double-blind, multicenter medical trial analyzing the security and immune reactions of TNF-K.